SOPHiA GENETICS reported fourth‑quarter 2025 revenue of $21.7 million, a 22 % year‑over‑year increase that surpassed analyst consensus of roughly $20.94 million. The company posted a loss per share of $0.28, missing the consensus estimate of a loss between $0.20 and $0.24 per share. The miss was largely attributable to one‑time litigation expenses and foreign‑exchange headwinds that increased operating costs.
Adjusted gross margin expanded to 74.2 %, up 140 basis points from 73.0 % in 2024, driven by higher utilization of the SOPHiA DDM platform and cost efficiencies. The platform processed 40 % more terabytes than the prior year, supporting the margin lift despite higher operating expenses.
Management reaffirmed its 2026 revenue guidance of $92 million to $94 million, a 20 % to 22 % increase from the prior year, and reiterated an adjusted EBITDA loss forecast of $29 million to $32 million. The guidance signals confidence that the platform will continue to scale and that operating leverage will improve in 2026.
The company faced headwinds from foreign‑exchange headwinds due to the appreciation of the Swiss franc, which increased U.S. dollar‑denominated costs, and from litigation expenses related to patent‑infringement claims with Guardant Health. These factors contributed to the Q4 operating expense increase to $33.2 million from $29.5 million in the prior year.
CEO Jurgi Camblong said, 'We finished 2025 strong, with Q4 revenue growing 22% and full‑year revenue increasing 19% year‑over‑year, as our growth momentum continues to accelerate.' He added, 'We also continued to demonstrate the scalability of our AI‑native precision medicine platform, SOPHiA DDMTM, as adjusted gross margin expanded 140 basis points year‑over‑year to 74.2% in 2025, even as total terabytes processed by the Platform increased 40% in the same period.' CFO George Cardoza noted, 'We remain confident in our current capital position with respect to the achievement of our long‑term goals.'
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.